Drug Interactions

  • Laurent P. Rivory
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Drug–drug interactions in cancer patients are relatively common and can and do have significant impact on outcomes. Increasingly, it is being recognized that these arise through the complex interplay of drugs with both metabolic and transport processes. The complexity is increased through the time lags that may occur between the administration of interacting drugs, the fact that some drugs can both induce and inhibit metabolism, and the inhibition of multiple pathways by some. The potential for drug–drug interaction needs to be considered in the development of new drugs as well as in the routine use of existing agents.


drug-drug interactions Drug metabolism Drug disposition Transporters 


  1. 1.
    Balis FM (1986) Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet 11:223–235PubMedGoogle Scholar
  2. 2.
    Loadman PM, Bibby MC (1994) Pharmacokinetic drug interactions with anticancer drugs. Clin Pharmacokinet 26:486–500PubMedGoogle Scholar
  3. 3.
    McLeod HL (1998) Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 45:539–544PubMedGoogle Scholar
  4. 4.
    van Meerten E, Verweij J, Schellens JH (1995) Antineoplastic agents. Drug interactions of clinical significance. Drug Saf 12:168–182PubMedGoogle Scholar
  5. 5.
    Relling MV, Pui CH, Sandlund JT, Rivera GK, Hancock ML, Boyett JM et al (2000) Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356:285–290PubMedGoogle Scholar
  6. 6.
    Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ et al (1995) Cyclophosphamide metabolism in children. Cancer Res 55:803–809PubMedGoogle Scholar
  7. 7.
    Sparreboom A, Cox MC, Acharya MR, Figg WD (2004) Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22:2489–2503PubMedGoogle Scholar
  8. 8.
    Yu DK (1999) The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39:1203–1211PubMedGoogle Scholar
  9. 9.
    Ayrton A, Morgan P (2008) Role of transport proteins in drug discovery and development: a pharmaceutical perspective. Xenobiotica 38:676–708PubMedGoogle Scholar
  10. 10.
    Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D et al (1998) Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4:941–948PubMedGoogle Scholar
  11. 11.
    Nimmo W (1983) Drugs, diseases and altered gastric emptying. In: Gibaldi PP, Prescott L (eds) Handbook of clinical pharmacokinetics. ADIS Health Science, New YorkGoogle Scholar
  12. 12.
    Riccardi R, Balis FM, Ferrara P, Lasorella A, Poplack DG, Mastrangelo R (1986) Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 3:319–324PubMedGoogle Scholar
  13. 13.
    Pearson AD, Craft AW, Eastham EJ, Aherne GW, Littleton P, Pearson GL et al (1985) Small intestinal transit time affects methotrexate absorption in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 14:211–215PubMedGoogle Scholar
  14. 14.
    Hughes AN, Rafi I, Griffin MJ, Calvert AH, Newell DR, Calvete JA et al (1999) Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. Clin Cancer Res 5:111–118PubMedGoogle Scholar
  15. 15.
    Swaisland H, Laight A, Stafford L, Jones H, Morris C, Dane A et al (2001) Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 40:297–306PubMedGoogle Scholar
  16. 16.
    Akhtar S, Beckman RA, Mould DR, Doyle E, Fields SZ, Wright J (2000) Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan. Cancer Chemother Pharmacol 46:204–210PubMedGoogle Scholar
  17. 17.
    Beale P, Judson I, Moore S, Statkevich P, Marco A, Cutler DL et al (1999) Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. Cancer Chemother Pharmacol 44:389–394PubMedGoogle Scholar
  18. 18.
    Saven A, Cheung WK, Smith I, Moyer M, Johannsen T, Rose E et al (1996) Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol 14:978–983PubMedGoogle Scholar
  19. 19.
    Reigner B, Clive S, Cassidy J, Jodrell D, Schulz R, Goggin T et al (1999) Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol 43:309–315PubMedGoogle Scholar
  20. 20.
    Malingre MM, Schellens JH, Van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H et al (2001) The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br J Cancer 85:1472–1477PubMedCentralPubMedGoogle Scholar
  21. 21.
    Zimm S, Collins JM, O’Neill D, Chabner BA, Poplack DG (1983) Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 34:810–817PubMedGoogle Scholar
  22. 22.
    Balis FM, Holcenberg JS, Zimm S, Tubergen D, Collins JM, Murphy RF et al (1987) The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 41:384–387PubMedGoogle Scholar
  23. 23.
    Phillips TA, Howell A, Grieve RJ, Welling PG (1980) Pharmacokinetics of oral and intravenous fluorouracil in humans. J Pharm Sci 69:1428–1431PubMedGoogle Scholar
  24. 24.
    Diasio RB (2001) Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology (Williston Park) 15:21–26, discussion 27Google Scholar
  25. 25.
    Jones R, Twelves C (2001) Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil? Expert Opin Pharmacother 2:1495–1505PubMedGoogle Scholar
  26. 26.
    Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC et al (1996) Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14:3085–3096PubMedGoogle Scholar
  27. 27.
    Ayrton A, Morgan P (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469–497PubMedGoogle Scholar
  28. 28.
    Schellens JH, Malingre MM, Kruijtzer CM, Bardelmeijer HA, van Tellingen O, Schinkel AH et al (2000) Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 12:103–110PubMedGoogle Scholar
  29. 29.
    van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ et al (1997) Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76:1181–1183PubMedCentralPubMedGoogle Scholar
  30. 30.
    van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH (1998) Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res 4:2293–2297PubMedGoogle Scholar
  31. 31.
    Meerum Terwogt JM, Malingre MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ et al (1999) Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5:3379–3384PubMedGoogle Scholar
  32. 32.
    Britten CD, Baker SD, Denis LJ, Johnson T, Drengler R, Siu LL et al (2000) Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. Clin Cancer Res 6:3459–3468PubMedGoogle Scholar
  33. 33.
    Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH et al (2000) Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 6:4416–4421PubMedGoogle Scholar
  34. 34.
    Malingre MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM et al (2001) Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84:42–47PubMedCentralPubMedGoogle Scholar
  35. 35.
    Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH et al (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651–1656PubMedGoogle Scholar
  36. 36.
    Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M et al (2001) A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin Cancer Res 7:1221–1229PubMedGoogle Scholar
  37. 37.
    Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG (2000) The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 26:449–462PubMedGoogle Scholar
  38. 38.
    Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517–2524PubMedCentralPubMedGoogle Scholar
  39. 39.
    Hassan M, Nilsson C, Olsson H, Lundin J, Osterborg A (1999) The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma. Eur J Haematol 63:163–170PubMedGoogle Scholar
  40. 40.
    Hendrikse NH, de Vries EG, Eriks-Fluks L, van der Graaf WT, Hospers GA, Willemsen AT et al (1999) A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 59:2411–2416PubMedGoogle Scholar
  41. 41.
    Warren KE, Patel MC, McCully CM, Montuenga LM, Balis FM (2000) Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates. Cancer Chemother Pharmacol 45:207–212PubMedGoogle Scholar
  42. 42.
    Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L et al (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491–502PubMedGoogle Scholar
  43. 43.
    Bohme A, Ganser A, Hoelzer D (1995) Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 71:311–312PubMedGoogle Scholar
  44. 44.
    Gillies J, Hung KA, Fitzsimons E, Soutar R (1998) Severe vincristine toxicity in combination with itraconazole. Clin Lab Haematol 20:123–124PubMedGoogle Scholar
  45. 45.
    Toffoli G, Aita P, Sorio R, Corona G, Bertola A, Colussi AM et al (1999) Effect of cyclosporin A on protein binding of teniposide in cancer patients. Anticancer Drugs 10:511–518PubMedGoogle Scholar
  46. 46.
    Thummel KE, Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389–430PubMedGoogle Scholar
  47. 47.
    Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD (1999) Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 290:1116–1125PubMedGoogle Scholar
  48. 48.
    Ernest CS 2nd, Hall SD, Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583–591PubMedGoogle Scholar
  49. 49.
    Abduljalil K, Kinzig M, Bulitta J, Horkovics-Kovats S, Sorgel F, Rodamer M et al (2009) Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. Antimicrob Agents Chemother 53:2892–2901PubMedCentralPubMedGoogle Scholar
  50. 50.
    Weaver RJ (2001) Assessment of drug-drug interactions: concepts and approaches. Xenobiotica 31:499–538PubMedGoogle Scholar
  51. 51.
    Mayhew BS, Jones DR, Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031–1037PubMedGoogle Scholar
  52. 52.
    Zhang L, Zhang YD, Zhao P, Huang SM (2009) Predicting drug-drug interactions: an FDA perspective. AAPS J 11:300–306PubMedGoogle Scholar
  53. 53.
    Nomeir AA, Palamanda JR, Favreau L (2008) Identification of CYP mechanism-based inhibitors. In: Yan Z, Caldwell GW (eds) Optimization in drug discovery: in vitro methods. Humana, Totowa, NJ, pp 245–262Google Scholar
  54. 54.
    Okuda H, Ogura K, Kato A, Takubo H, Watabe T (1998) A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 287:791–799PubMedGoogle Scholar
  55. 55.
    Nakayama H, Kinouchi T, Kataoka K, Akimoto S, Matsuda Y, Ohnishi Y (1997) Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics 7:35–43PubMedGoogle Scholar
  56. 56.
    Yan J, Tyring SK, McCrary MM, Lee PC, Haworth S, Raymond R et al (1997) The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. Clin Pharmacol Ther 61:563–573PubMedGoogle Scholar
  57. 57.
    Desgranges C, Razaka G, De Clercq E, Herdewijn P, Balzarini J, Drouillet F et al (1986) Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res 46:1094–1101PubMedGoogle Scholar
  58. 58.
    Ahmed FY, Johnston SJ, Cassidy J, O’Kelly T, Binnie N, Murray GI et al (1999) Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. J Clin Oncol 17:2439–2445PubMedGoogle Scholar
  59. 59.
    Evans TR, Di Salle E, Ornati G, Lassus M, Benedetti MS, Pianezzola E et al (1992) Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 52:5933–5939PubMedGoogle Scholar
  60. 60.
    Watanabe M, Tateishi T, Takezawa N, Tanaka M, Kumai T, Nakaya S et al (2001) Effects of PR-350, a newly developed radiosensitizer, on dihydropyrimidine dehydrogenase activity and 5-fluorouracil pharmacokinetics. Cancer Chemother Pharmacol 47:250–254PubMedGoogle Scholar
  61. 61.
    Yamazaki S, Hayashi M, Toth LN, Ozawa N (2001) Lack of interaction between bropirimine and 5-fluorouracil on human dihydropyrimidine dehydrogenase. Xenobiotica 31:25–31PubMedGoogle Scholar
  62. 62.
    Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA et al (2002) The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol 53:67–74PubMedGoogle Scholar
  63. 63.
    Mounier N, Katlama C, Costagliola D, Chichmanian RM, Spano JP (2009) Drug interactions between antineoplastic and antiretroviral therapies: implications and management for clinical practice. Crit Rev Oncol Hematol 72:10–20PubMedGoogle Scholar
  64. 64.
    Bosque E (2001) Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy. Ann Intern Med 134:427PubMedGoogle Scholar
  65. 65.
    Yule SM, Walker D, Cole M, McSorley L, Cholerton S, Daly AK et al (1999) The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab Dispos 27:417–421PubMedGoogle Scholar
  66. 66.
    Lorusso P, Heath EI, McGreivy J, Sun YN, Melara R, Yan L et al (2008) Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors. Invest New Drugs 26:455–462PubMedGoogle Scholar
  67. 67.
    Goel S, Cohen M, Comezoglu SN, Perrin L, Andre F, Jayabalan D et al (2008) The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res 14:2701–2709PubMedGoogle Scholar
  68. 68.
    Trachtenberg J, Halpern N, Pont A (1983) Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol 130:152–153PubMedGoogle Scholar
  69. 69.
    Reid AH, Attard G, Barrie E, de Bono JS (2008) CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 5:610–620PubMedGoogle Scholar
  70. 70.
    Amato RJ, Teh BS, Henary H, Khan M, Saxena S (2009) A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate. Urol Oncol 27:165–169PubMedGoogle Scholar
  71. 71.
    Dodds HM, Haaz MC, Riou JF, Robert J, Rivory LP (1998) Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 286:578–583PubMedGoogle Scholar
  72. 72.
    Haaz MC, Rivory L, Riche C, Vernillet L, Robert J (1998) Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 58:468–472PubMedGoogle Scholar
  73. 73.
    Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW (1994) Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543–5546PubMedGoogle Scholar
  74. 74.
    Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296–1302PubMedGoogle Scholar
  75. 75.
    Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A (2002) Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 20:3122–3129PubMedGoogle Scholar
  76. 76.
    Ong CE, Coulter S, Birkett DJ, Bhasker CR, Miners JO (2000) The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol 50:573–580PubMedGoogle Scholar
  77. 77.
    Jamis-Dow CA, Klecker RW, Katki AG, Collins JM (1995) Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 36:107–114PubMedGoogle Scholar
  78. 78.
    Jamis-Dow CA, Pearl ML, Watkins PB, Blake DS, Klecker RW, Collins JM (1997) Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole. Am J Clin Oncol 20:592–599PubMedGoogle Scholar
  79. 79.
    Siegsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman MM (1994) Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 151:485–491PubMedGoogle Scholar
  80. 80.
    Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ et al (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16:408–414PubMedGoogle Scholar
  81. 81.
    Fischer V, Rodriguez-Gascon A, Heitz F, Tynes R, Hauck C, Cohen D et al (1998) The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 26:802–811PubMedGoogle Scholar
  82. 82.
    Ng SF, Waxman DJ (1991) N, N′, N″-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents. Cancer Res 51:2340–2345PubMedGoogle Scholar
  83. 83.
    Huitema AD, Kerbusch T, Tibben MM, Rodenhuis S, Beijnen JH (2000) Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemother Pharmacol 46:119–127PubMedGoogle Scholar
  84. 84.
    Rae JM, Soukhova NV, Flockhart DA, Desta Z (2002) Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 30:525–530PubMedGoogle Scholar
  85. 85.
    Ren S, Slatterly JT (1999) Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine. AAPS PharmSci 1:E14PubMedGoogle Scholar
  86. 86.
    Gilbar PJ, Brodribb TR (2001) Phenytoin and fluorouracil interaction. Ann Pharmacother 35:1367–1370PubMedGoogle Scholar
  87. 87.
    Kolesar JM, Johnson CL, Freeberg BL, Berlin JD, Schiller JH (1999) Warfarin-5-FU interaction – a consecutive case series. Pharmacotherapy 19:1445–1449PubMedGoogle Scholar
  88. 88.
    Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85–104PubMedGoogle Scholar
  89. 89.
    Shah HR, Ledbetter L, Diasio R, Saif MW (2006) A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. Clin Colorectal Cancer 5:354–358PubMedGoogle Scholar
  90. 90.
    Zandvliet AS, Huitema AD, Copalu W, Yamada Y, Tamura T, Beijnen JH et al (2007) CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clin Cancer Res 13:2970–2976PubMedGoogle Scholar
  91. 91.
    Siegel-Lakhai WS, Zandvliet AS, Huitema AD, Tibben MM, Milano G, Girre V et al (2008) A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumors. Br J Cancer 98:1320–1326PubMedCentralPubMedGoogle Scholar
  92. 92.
    Konishi H, Yoshimoto T, Morita K, Minouchi T, Sato T, Yamaji A (2003) Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in rats. J Pharm Pharmacol 55:143–149PubMedGoogle Scholar
  93. 93.
    Brickell K, Porter D, Thompson P (2003) Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports. Br J Cancer 89:615–616PubMedCentralPubMedGoogle Scholar
  94. 94.
    Yoshisue K, Nagayama S, Shindo T, Kawaguchi Y (2001) Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats. J Pharmacol Exp Ther 297:1166–1175PubMedGoogle Scholar
  95. 95.
    Tsuda A, Fujiyama J, Miki A, Hori S, Ohtani H, Sawada Y (2008) The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium. Cancer Chemother Pharmacol 62:427–432PubMedGoogle Scholar
  96. 96.
    Kinikar SA, Kolesar JM (1999) Identification of a gemcitabine-warfarin interaction. Pharmacotherapy 19:1331–1333PubMedGoogle Scholar
  97. 97.
    Kilgour-Christie J, Czarnecki A (2002) Gemcitabine and the interaction with anticoagulants. Lancet Oncol 3:460PubMedGoogle Scholar
  98. 98.
    Morgan ET (2001) Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos 29:207–212PubMedGoogle Scholar
  99. 99.
    Rivory LP, Slaviero KA, Clarke SJ (2002) Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 87:277–280PubMedCentralPubMedGoogle Scholar
  100. 100.
    Danhauser LL, Freimann JH Jr, Gilchrist TL, Gutterman JU, Hunter CY, Yeomans AC et al (1993) Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol 11:751–761PubMedGoogle Scholar
  101. 101.
    Grem JL, McAtee N, Murphy RF, Balis FM, Cullen E, Chen AP et al (1997) A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. Clin Cancer Res 3:1125–1134PubMedGoogle Scholar
  102. 102.
    Kim J, Zhi J, Satoh H, Koss-Twardy SG, Passe SM, Patel IH et al (1998) Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma. Anticancer Drugs 9:689–696PubMedGoogle Scholar
  103. 103.
    Yee LK, Allegra CJ, Steinberg SM, Grem JL (1992) Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a. J Natl Cancer Inst 84:1820–1825PubMedGoogle Scholar
  104. 104.
    Grenader T, Gipps M, Shavit L, Gabizon A (2007) Significant drug interaction: phenytoin toxicity due to erlotinib. Lung Cancer 57:404–406PubMedGoogle Scholar
  105. 105.
    Boruban MC, Yasar U, Babaoglu MO, Sencan O, Bozkurt A (2006) Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother 18:421–424PubMedGoogle Scholar
  106. 106.
    Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17PubMedGoogle Scholar
  107. 107.
    Harmsen S, Meijerman I, Beijnen JH, Schellens JH (2007) The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat Rev 33:369–380PubMedGoogle Scholar
  108. 108.
    Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ (1999) Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 66:589–593PubMedGoogle Scholar
  109. 109.
    Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J et al (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516–1525PubMedGoogle Scholar
  110. 110.
    Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH (1992) Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 10:311–315PubMedGoogle Scholar
  111. 111.
    Zamboni WC, Gajjar AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ et al (1998) Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 4:783–789PubMedGoogle Scholar
  112. 112.
    Anderson CD, Wang J, Kumar GN, McMillan JM, Walle UK, Walle T (1995) Dexamethasone induction of taxol metabolism in the rat. Drug Metab Dispos 23:1286–1290PubMedGoogle Scholar
  113. 113.
    Monsarrat B, Chatelut E, Royer I, Alvinerie P, Dubois J, Dezeuse A et al (1998) Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 26:229–233PubMedGoogle Scholar
  114. 114.
    Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM et al (2001) Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 29:242–251PubMedGoogle Scholar
  115. 115.
    Chang TK, Yu L, Maurel P, Waxman DJ (1997) Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 57:1946–1954PubMedGoogle Scholar
  116. 116.
    Riva M, Landonio G, Defanti CA, Siena S (2000) The effect of anticonvulsant drugs on blood levels of methotrexate. J Neurooncol 48:249–250PubMedGoogle Scholar
  117. 117.
    Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN et al (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635–1642PubMedGoogle Scholar
  118. 118.
    Aherne GW, Piall E, Marks V, Mould G, White WF (1978) Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br Med J 1:1097–1099PubMedCentralPubMedGoogle Scholar
  119. 119.
    Blum R, Seymour JF, Toner G (2002) Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. Ann Oncol 13:327–330PubMedGoogle Scholar
  120. 120.
    Dalle JH, Auvrignon A, Vassal G, Leverger G (2002) Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol Oncol 24:321–322PubMedGoogle Scholar
  121. 121.
    Ronchera CL, Hernandez T, Peris JE, Torres F, Granero L, Jimenez NV et al (1993) Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther Drug Monit 15:375–379PubMedGoogle Scholar
  122. 122.
    Uwai Y, Saito H, Inui K (2000) Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol 409:31–36PubMedGoogle Scholar
  123. 123.
    Sweeney CJ, Takimoto CH, Latz JE, Baker SD, Murry DJ, Krull JH et al (2006) Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer. Clin Cancer Res 12:536–542PubMedGoogle Scholar
  124. 124.
    Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J (2000) Potential interaction between methotrexate and omeprazole. Ann Pharmacother 34:1024–1027PubMedGoogle Scholar
  125. 125.
    Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H et al (2009) Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 67:44–49PubMedGoogle Scholar
  126. 126.
    Donelli MG, Zucchetti M, Munzone E, D’Incalci M, Crosignani A (1998) Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 34:33–46PubMedGoogle Scholar
  127. 127.
    Koren G, Beatty K, Seto A, Einarson TR, Lishner M (1992) The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 26:363–371PubMedGoogle Scholar
  128. 128.
    Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E et al (1997) Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15:1906–1915PubMedGoogle Scholar
  129. 129.
    Booth CL, Brouwer KR, Brouwer KL (1998) Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer Res 58:3641–3648PubMedGoogle Scholar
  130. 130.
    Smit JW, Duin E, Steen H, Oosting R, Roggeveld J, Meijer DK (1998) Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level. Br J Pharmacol 123:361–370PubMedGoogle Scholar
  131. 131.
    Schuetz EG, Beck WT, Schuetz JD (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311–318PubMedGoogle Scholar
  132. 132.
    Yokoo K, Hamada A, Tazoe K, Sasaki Y, Saito H (2009) Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer. Ther Drug Monit 31:400–403PubMedGoogle Scholar
  133. 133.
    Yokoo K, Watanabe H, Hamada A, Masa K, Saito H, Terazaki H et al (2006) Effect of S-1 on pharmacokinetics of irinotecan in a patient with colorectal cancer. Clin Pharmacol Ther 80:422–424PubMedGoogle Scholar
  134. 134.
    Millward MJ, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JF et al (1998) Phase I trial of cremophor EL with bolus doxorubicin. Clin Cancer Res 4:2321–2329PubMedGoogle Scholar
  135. 135.
    Badary OA, Abdel-Naim AB, Khalifa AE, Hamada FM (2000) Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL. Naunyn Schmiedebergs Arch Pharmacol 361:339–344PubMedGoogle Scholar
  136. 136.
    de Vos AI, Nooter K, Verweij J, Loos WJ, Brouwer E, de Bruijn P et al (1997) Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL. Ann Oncol 8:1145–1150PubMedGoogle Scholar
  137. 137.
    Badary OA, Al-Shabanah OA, Al-Gharably NM, Elmazar MM (1998) Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice. Anticancer Drugs 9:809–815PubMedGoogle Scholar
  138. 138.
    Webster LK, Cosson EJ, Stokes KH, Millward MJ (1996) Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 73:522–524PubMedCentralPubMedGoogle Scholar
  139. 139.
    Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G et al (1996) Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14:2713–2721PubMedGoogle Scholar
  140. 140.
    Moreira A, Lobato R, Morais J, Silva S, Ribeiro J, Figueira A et al (2001) Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Cancer Chemother Pharmacol 48:333–337PubMedGoogle Scholar
  141. 141.
    Ellis AG, Webster LK (1999) Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. Cancer Chemother Pharmacol 43:13–18PubMedGoogle Scholar
  142. 142.
    Cummings J, Forrest GJ, Cunningham D, Gilchrist NL, Soukop M (1986) Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients. Cancer Chemother Pharmacol 17:80–84PubMedGoogle Scholar
  143. 143.
    Paal K, Horvath J, Csaki C, Ferencz T, Schuler D, Borsi JD (1998) Effect of etoposide on the pharmacokinetics of methotrexate in vivo. Anticancer Drugs 9:765–772PubMedGoogle Scholar
  144. 144.
    Fuhr U, Weiss M, Kroemer HK, Neugebauer G, Rameis H, Weber W et al (1996) Systematic screening for pharmacokinetic interactions during drug development. Int J Clin Pharmacol Ther 34:139–151PubMedGoogle Scholar
  145. 145.
    Rodrigues AD, Winchell GA, Dobrinska MR (2001) Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases. J Clin Pharmacol 41:368–373PubMedGoogle Scholar
  146. 146.
    Bonnabry P, Sievering J, Leemann T, Dayer P (2001) Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. Clin Pharmacokinet 40:631–640PubMedGoogle Scholar
  147. 147.
    Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465–480PubMedGoogle Scholar
  148. 148.
    Crespi CL, Stresser DM (2000) Fluorometric screening for metabolism-based drug–drug interactions. J Pharmacol Toxicol Methods 44:325–331PubMedGoogle Scholar
  149. 149.
    Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP et al (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440–1448PubMedGoogle Scholar
  150. 150.
    Crespi CL, Fox L, Stocker P, Hu M, Steimel DT (2000) Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression. Eur J Pharm Sci 12:63–68PubMedGoogle Scholar
  151. 151.
    Gurtoo HL, Marinello AJ, Struck RF, Paul B, Dahms RP (1981) Studies on the mechanism of denaturation of cytochrome P-450 by cyclophosphamide and its metabolites. J Biol Chem 256:11691–11701PubMedGoogle Scholar
  152. 152.
    Chang TK, Waxman DJ (1993) Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard. Cancer Res 53:2490–2497PubMedGoogle Scholar
  153. 153.
    Baumhakel M, Kasel D, Rao-Schymanski RA, Bocker R, Beckurts KT, Zaigler M et al (2001) Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 39:517–528PubMedGoogle Scholar
  154. 154.
    Rodrigues AD, Lin JH (2001) Screening of drug candidates for their drug–drug interaction potential. Curr Opin Chem Biol 5:396–401PubMedGoogle Scholar
  155. 155.
    Bisogno G, Cowie F, Boddy A, Thomas HD, Dick G, Pinkerton CR (1998) High-dose cyclosporin with etoposide – toxicity and pharmacokinetic interaction in children with solid tumors. Br J Cancer 77:2304–2309PubMedCentralPubMedGoogle Scholar
  156. 156.
    Murray LS, Jodrell DI, Morrison JG, Cook A, Kerr DJ, Whiting B et al (1998) The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction. Clin Oncol (R Coll Radiol) 10:35–38Google Scholar
  157. 157.
    Kamataki T, Yokoi T, Fujita K, Ando Y (1998) Preclinical approach for identifying drug interactions. Cancer Chemother Pharmacol 42(Suppl):S50–S53PubMedGoogle Scholar
  158. 158.
    Lovless H, Arena E, Felsted RL, Bachur NR (1978) Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res 38:593–598Google Scholar
  159. 159.
    Guengerich FP (1997) Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 106:161–182PubMedGoogle Scholar
  160. 160.
    Turesky RJ, Constable A, Fay LB, Guengerich FP (1999) Interspecies differences in metabolism of heterocyclic aromatic amines by rat and human P450 1A2. Cancer Lett 143:109–112PubMedGoogle Scholar
  161. 161.
    Boobis AR, Sesardic D, Murray BP, Edwards RJ, Singleton AM, Rich KJ et al (1990) Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors. Xenobiotica 20:1139–1161PubMedGoogle Scholar
  162. 162.
    Waxman DJ (1999) P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 369:11–23PubMedGoogle Scholar
  163. 163.
    Bauer LA, Horn JR, Pettit H (1996) Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations. Ther Drug Monit 18:46–52PubMedGoogle Scholar
  164. 164.
    Grasela TH Jr, Antal EJ, Ereshefsky L, Wells BG, Evans RL, Smith RB (1987) An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction. Clin Pharmacol Ther 42:433–441PubMedGoogle Scholar
  165. 165.
    Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK (2007) Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99:592–600PubMedGoogle Scholar
  166. 166.
    Hsu A, Granneman GR, Bertz RJ (1998) Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275–291PubMedGoogle Scholar
  167. 167.
    Schilsky RL, Levin J, West WH, Wong A, Colwell B, Thirlwell MP et al (2002) Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 20:1519–1526PubMedGoogle Scholar
  168. 168.
    Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C et al (2001) Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29:1454–1459PubMedGoogle Scholar
  169. 169.
    Rivory LP, Slaviero KA, Hoskins JM, Clarke SJ (2001) The erythromycin breath test for the prediction of drug clearance. Clin Pharmacokinet 40:151–158PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Faculty of ScienceThe University of New South WalesSydneyAustralia

Personalised recommendations